文章：

MEK抑制剂作为多发性骨髓瘤的化疗干预

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

原文发布日期：2013-03-22

DOI: 10.1038/bcj.2013.1

类型: Review

开放获取: 是

英文摘要：

The Ras/Raf/MEK/extracellular signal regulated kinase (ERK) (Ras/mitogen-activated protein kinases (MAPK)) signal transduction pathway is a crucial mediator of many fundamental biological processes, including cellular proliferation, survival, angiogenesis and migration. Aberrant signalling through the Ras/MAPK cascade is common in a wide array of malignancies, including multiple myeloma (MM), making it an appealing candidate for the development of novel targeted therapies. In this review, we explore our current understanding of the Ras/MAPK pathway and its role in MM. Additionally, we summarise the current status of small molecule inhibitors of MEK under clinical evaluation, and discuss future approaches required to optimise their use.

摘要翻译： 

Ras/Raf/MEK/细胞外信号调节激酶（ERK）（即Ras/丝裂原活化蛋白激酶（MAPK））信号转导通路是细胞增殖、存活、血管生成及迁移等诸多基本生物学过程的关键调控者。该信号通路的异常激活在多种恶性肿瘤（包括多发性骨髓瘤）中十分常见，使其成为开发新型靶向治疗的重要靶点。本文综述了目前对Ras/MAPK通路及其在多发性骨髓瘤中作用机制的认识，系统归纳了处于临床评估阶段的MEK小分子抑制剂研究现状，并探讨了优化其临床应用的未来研究方向。

原文链接：

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma